Intrinsic Value of S&P & Nasdaq Contact Us

Virax Biolabs Group Limited VRAX NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • GB • USD

SharesGrow Score
48/100
2/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$1.00
+567.6%

There have been 6 recent insider transactions recorded for Virax Biolabs Group Limited (VRAX), including 0 buys and 0 sells.

Notable insiders with recent activity include Davis Jason, Foster James Alexander Cunliffe, Miller Iain David. Insider transactions can provide insights into how company leadership views the stock's valuation and future prospects.

Insider Transactions — VRAX

Date Name Role Transaction Shares Avg. Price Value Shares Owned
2026-03-18 Davis Jason Officer Unknown - - - -
2026-03-18 Foster James Alexander Cunliffe Chief Executive Officer Unknown 31,975 $0.88 $28.14K -
2026-03-18 Miller Iain David Officer Unknown - - - -
2026-03-18 Norton Evan Michael Director Unknown 10,000 $0.88 $8.8K -
2026-03-18 Mccracken Nigel William Chief Operating Officer Unknown 29,416 $0.88 $25.89K -
2026-03-18 Haight Nelson M Director Unknown 10,000 $0.88 $8.8K -
Informative Buy/Sell — open market transaction (most significant) Uninformative Buy — award, option exercise, conversion Uninformative Sell — tax withholding, award vest sale Neutral — gift, trust, expiry
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message